8 documents found, page 1 of 1
Significance of Furin Expression in Thyroid Neoplastic Transformation
Azevedo, Maria Teresa; Macedo, Sofia; Canberk, Sule; Cardoso, Luís; Gaspar, Tiago Bordeira; Pestana, Ana; Batista, Rui; Sobrinho-Simões, ManuelAngiotensin-Converting Enzyme 2 (ACE2), Transmembrane Serine Protease 2 (TMPRSS2), and Furin were known to be key players in the SARS-CoV-2 infection, and the thyroid gland was revealed to be one of the relevant targets of the virus. Regardless of the viral infection, the expression of these molecules in the thyroid gland and their putative role in the neoplastic transformation of the thyrocytes has not been th...
Comprehensive Assessment of TERT mRNA Expression across a Large Cohort of Benig...
Pestana, Ana; Batista, Rui; Celestino, Ricardo; Canberk, Sule; Sobrinho-Simões, Manuel; Soares, PaulaThe presence of TERT promoter (TERTp) mutations in thyroid cancer have been associated with worse prognosis features, whereas the extent and meaning of the expression and activation of TERT in thyroid tumours is still largely unknown. We analysed frozen samples from a series of benign and malignant thyroid tumours, displaying non-aggressive features and low mutational burden in order to evaluate the presence of...
NIS expression in thyroid tumors, relation with prognosis clinicopathological a...
Tavares, Catarina; Coelho, Maria João; Eloy, Catarina; Melo, Miguel; da Rocha, Adriana Gaspar; Pestana, Ana; Batista, Rui; Ferreira, Luciana BuenoThyroid cancer therapy is based on surgery followed by radioiodine treatment. The incorporation of radioiodine by cancer cells is mediated by sodium iodide symporter (NIS) (codified by the SLC5A5 gene), that is functional only when targeted to the cell membrane. We aimed to evaluate if NIS expression in thyroid primary tumors would be helpful in predicting tumor behavior, response to therapy and prognosis. NIS ...
mTOR Pathway in Papillary Thyroid Carcinoma: Different Contributions of mTORC1 ...
Tavares, Catarina; Eloy, Catarina; Melo, Miguel; Gaspar da Rocha, Adriana; Pestana, Ana; Batista, Rui; Bueno Ferreira, Luciana; Rios, ElisabeteThe mammalian target of rapamycin (mTOR) pathway is overactivated in thyroid cancer (TC). We previously demonstrated that phospho-mTOR expression is associated with tumor aggressiveness, therapy resistance, and lower mRNA expression of SLC5A5 in papillary thyroid carcinoma (PTC), while phospho-S6 (mTORC1 effector) expression was associated with less aggressive clinicopathological features. The distinct behavior...
CRABP1, C1QL1 and LCN2 are biomarkers of differentiated thyroid carcinoma, and ...
Celestino, Ricardo; Nome, Torfinn; Pestana, Ana; Hoff, Andreas M.; Gonçalves, A. Pedro; Pereira, Luísa; Cavadas, Bruno; Eloy, Catarina; Bjøro, TrineBackground: The prognostic variability of thyroid carcinomas has led to the search for accurate biomarkers at the molecular level. Follicular thyroid carcinoma (FTC) is a typical example of differentiated thyroid carcinomas (DTC) in which challenges are faced in the differential diagnosis. Methods: We used high-throughput paired-end RNA sequencing technology to study four cases of FTC with different degree of c...
TERT promoter mutations in pancreatic endocrine tumours are rare and mainly fou...
Vinagre, João; Nabais, Joana; Pinheiro, Jorge; Batista, Rui; Oliveira, Rui Caetano; Gonçalves, António Pedro; Pestana, Ana; Reis, MartaOne of the hallmarks of cancer is its unlimited replicative potential that needs a compensatory mechanism for the consequential telomere erosion. Telomerase promoter (TERTp) mutations were recently reported as a novel mechanism for telomerase re-activation/expression in order to maintain telomere length. Pancreatic endocrine tumors (PETs) were so far recognized to rely mainly on the alternative lengthening of t...
Low frequency of TERT promoter mutations in gastrointestinal stromal tumors (GI...
Reis, R. M.; Campanella, Nathália C.; Celestino, Ricardo; Pestana, Ana; Scapulatempo-Neto, Cristovam; Oliveira, Antônio Talvane TorresSomatic mutations in the promoter region of telomerase reverse transcriptase (TERT) gene, mainly at positions c. − 124 and c. − 146 bp, are frequent in several human cancers; yet its presence in gastrointestinal stromal tumor (GIST) has not been reported to date. Herein, we searched for the presence and clinicopathological association of TERT promoter mutations in genomic DNA from 130 bona fide GISTs. We found ...
Low frequency of TERT promoter mutations in gastrointestinal stromal tumors (GI...
Campanella, Natália C; Celestino, Ricardo; Pestana, Ana; Scapulatempo-Neto, C; Oliveira, Antonio Talvane de; Brito, Maria josé; Gouveia, AntónioSomatic mutations in the promoter region of telomerase reverse transcriptase (TERT) gene, mainly at positions c.-124 and c.-146 bp, are frequent in several human cancers; yet its presence in gastrointestinal stromal tumor (GIST) has not been reported to date. Herein, we searched for the presence and clinicopathological association of TERT promoter mutations in genomic DNA from 130 bona fide GISTs. We found TERT...